isabelobrien, Author at European Medical Journal - Page 6 of 65

An illustration of two people's hands shaking, wearing suits

Roche acquires US biotech 89bio for $3.5bn

Roche acquires 89bio in a $3.5bn deal, adding a late-stage MASH therapy and expanding its focus on cardiovascular and metabolic diseases.

Person typing on computer

New study reveals risks of patients using ChatGPT

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

A traditional row of german houses with a german flag flying from a roof.

Pharma in Germany

The pharma sector in Germany has research, investment and access to medicine to its name, but how can it reclaim its innovation crown?

Magnifying glass on upward trajectory

GLP-1 therapies in trials for 100+ diseases, Phesi finds

Phesi analysis shows GLP-1 therapies moving beyond diabetes and obesity into 100+ diseases, from cancer to cardiovascular conditions.

Coins falling

ABPI report highlights decline in UK pharma investment

The latest ABPI and PwC Pharmaceutical Competitiveness Framework reveals the UK is losing ground in pharma R&D, investment, and clinical trials, with rankings slipping sharply since 2018.

Konstanze Döhner, President Elect, European Hematology Association (EHA); Department of Internal Medicine III, University Hospital of Ulm, Germany.

EHA Interview 2025: Konstanze Döhner

EMJ spoke with Konstanze Döhner, President Elect of the European Hematology Association, about her priorities for the future of haematology, challenges in research and patient care, and the vision behind the EHA2025 theme “Borderless Hematology”.

Martin Dreyling, Professor of Medicine and Head of the Lymphoma Programme, Ludwig Maximilian University, Germany; Scientific Program Committee Chair EHA2025 European Hematology Association (EHA)

EHA Interview 2025: Martin Dreyling

EMJ spoke with Martin Dreyling, Chair of the EHA2025 Scientific Program Committee, about his career journey, what attendees can expect from the upcoming congress, and the vision behind its programme.

Novo Nordisk cuts jobs to fund diabetes and obesity growth

Novo Nordisk announces 9,000 job cuts to streamline operations and reinvest in diabetes and obesity growth, aiming for long-term efficiency.

5 minutes with Fabrice Chouraqui, CEO, Pharming

Pharming’s CEO explores his journey into the pharmaceutical industry, a typical day for a CEO and his thoughts on leadership.

Lilly's TuneLab to share AI models with small biotechs

Lilly has launched TuneLab, giving biotech companies access to AI-powered drug discovery models based on over £1bn in research investment.